EMA Authorised: Sivextro (tedizolid) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Sivextro (tedizolid) by Merck Sharp & Dohme B.V. for the treatment of soft tissue infections and bacterial skin disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin and Soft Tissue Infections
• Soft Tissue Infections

Drugs mentioned

• Sivextro (tedizolid)

Snippet

Status: Authorised. Therapeutic area: Soft Tissue Infections;Skin Diseases, Bacterial. MAH: Merck Sharp & Dohme B.V.. Decision date: 28/02/2025